Pharma Intelligence Apps

UK Adults Call on Pharma Companies to Keep Improving COVID-19 Treatments Without Sidelining Other Conditions

06 Jan 2022

London, 04.01.22 – Pharmaceutical companies must keep improving COVID-19 treatments in line with new variants without sidelining work in other areas of health, according to new data from YouGov and Informa Pharma Intelligence, the world’s leading intelligence provider for the biopharma industry.

Citeline, Trialtrove

2020 Clinical Trials Roundup: Disruptions to the Trial Landscape

03 Nov 2021

Our annual analysis dissects the data of all Phase I–III clinical trials that started in a year dominated by COVID-19.

Biomedtracker, Datamonitor Healthcare

2020 Deal-Making Roundup

21 Sep 2021

Against a backdrop of unprecedented disruption, the biopharma and medtech industries reached incredible heights for deal-making activity during 2020.

Q2 2021 Clinical Trials and the COVID-19 Vaccine Pulse Report

By Karen Currie 03 Jun 2021

The goal of our second Clinical Trials & the COVID-19 Vaccine Pulse Report is to uncover who is still hesitant to take a vaccine, and what public health experts from pharma to the U.S. government can do to turn the tide.

Trialtrove

2020 Completed Trials A Bumpy Road for Industry Sponsored Clinical Studies

20 May 2021

Over the past five years, our analysis of completed trials consistently observed growth trends.

Clinical Trial Webinar Series

16 Apr 2021

Learn about the latest trends affecting biopharma R&D including, study diversity & transparency, predictive feasibility and more...

Scrip

How COVID-19 Defined 2020 For Biopharma

By Alaric DeArment 31 Dec 2020

Development of vaccines usually takes years, but drug makers whittled the process down to a matter of months amid a concerted response to a global health threat.

Generics Bulletin

EU Reforms Must Heed Pandemic Lessons

By David Wallace 08 Dec 2020

Reforms set out by the European Commission to better prepare the EU for future health crises must heed key lessons learned from experiences of the COVID-19 pandemic, such as the benefits of digitalization, Medicines for Europe has urged

Pink Sheet

With Warp Speed Decisions Already Made, Transitioning To Biden Admin Should Be No Trouble, Slaoui Says

By Derrick Gingery 08 Dec 2020

As vaccines near availability, Moncef Slaoui says his full-time role at OWS may be ending. He has not met with the Biden Transition team, but notes that other Warp Speed officials have.